Results 1 to 10 of about 67,411 (205)

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer

British Journal of Cancer, 2008
J-L Lee, H J Kang, K-H Lee
exaly  

Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature

Annals of Oncology, 2005
B T Hennessy, Gabriel N Hortobagyi
exaly  

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine

Annals of Oncology, 2011
Giulio Metro, J Foglietta, M Russillo
exaly  

Multicenter phase II study of oral capecitabine (Xeloda“) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

Annals of Oncology, 2003
P Reichardt, P C Thuss-Patience, D G Kieback   +2 more
exaly  

Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer

Cancer Letters, 2014
Jinling Jiang, Yingyan Yu, Bingya Liu
exaly  

Slow dissolution behaviour of amorphous capecitabine

International Journal of Pharmaceutics, 2013
Jos H Beijnen, Jan H M Schellens
exaly  

Capecitabine

Drugs, 2012
Antona J Wagstaff, Tim Ibbotson, Wagstaff Antona J   +2 more
exaly  

Emergency use of uridine triacetate for the prevention and treatment of life‐threatening 5‐fluorouracil and capecitabine toxicity

Cancer, 2017
Wen Wee, Muhammad Wasif Saif, Bassel F El-Rayes   +2 more
exaly  

A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer

Annals of Oncology, 2004
S Y Song, S I Lee, H C Chung
exaly  

The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis

BMC Cancer, 2021
Background The role of capecitabine in neoadjuvant and adjuvant chemotherapy for early-stage triple-negative breast cancer (TNBC) is highly controversial.
Xingfa Huo, Jinming Li, Fuxing Zhao, Dengfeng Ren, Raees Ahmad, Xinyue Yuan, Feng Du, Jiuda Zhao   +7 more
doaj   +2 more sources